Vocxi Health

What Vocxi Health does

Vocxi Health is a Minnesota-based medical device company founded in 2022 that has developed MyBreathPrint, a graphene-enhanced breath-based diagnostic system designed to detect diseases, initially lung cancer, through analysis of volatile organic compounds (VOCs) in exhaled breath. The core technology pairs a graphene-based nanosensor array operating at parts-per-billion sensitivity with a proprietary wafer-scale single-monolayer receptor chemistry process, producing unique electrochemical BreathPrint patterns analyzed by the cloud-based BreathML machine learning platform. The system is protected by more than 30 issued patents with 30-plus pending, and has been validated through three IRB-approved human clinical studies covering 200 test subjects, with company-reported results showing 4x accuracy improvement over other screening approaches for stage-one lung cancer detection and 100% positive ease-of-use feedback.

The company is pre-commercialization, with primary go-to-market targeting clinicians, hospitals, and healthcare systems through an enterprise field-sales motion, initially via clinical study partnerships. Revenue mechanics are expected to combine hardware sales of the MyBreathPrint device—a handheld unit no larger than a deck of cards, developed in partnership with Forj Medical—with recurring subscription or per-use cloud analytics fees. A partnership with S3 Connected Health extends the platform into mobile and cloud-based patient monitoring via the Affinal digital health platform, and future plans include consumer/home use via a connected mobile application, broadening the addressable market beyond point-of-care screening. Customer segments span pulmonologists and oncologists at the point of care, healthcare payers seeking lower-cost alternatives to CT scans and biopsies, and eventually high-risk consumers for at-home screening.

Vocxi Health's leadership combines Boston Scientific veterans (CTO and scientific founder Greg Sherwood, COO Randy Schiestl, CPO Raia Finc) with University of Minnesota Medical Devices Center collaboration leadership (Senior Programs Director Greg Peterson) and a serial entrepreneur CEO (Ping Yeh, a cancer survivor). The company has raised a $1.6M SAFE seed round (December 2022) led by Engage Venture Partners with Morgan Evans joining the board, and is raising up to $5M via SAFEs (with $2.3M sold as of April 2023), supported by a broad network of angel investors across 10 states. Recognition includes Prix Galien USA Best Startup nomination (2025), SXSW Pitch finalist (2025), Startup World Cup Silicon Valley Regional champion (2025), Venture Summit West best Healthcare/Tech pitch (2024), and Blue Knight Symposium presenter (2024).

Name

Vocxi Health

Legal name

Vocxi Human Breath Intelligence

Website

https://vocxihealth.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Vocxi Health is a Minnesota-based medical device company developing MyBreathPrint, a graphene-enhanced breath-based diagnostic system that detects lung cancer and other diseases via volatile organic compound analysis, initially targeting clinicians and hospitals with plans for home use.

Ownership category

akta.pro rank

Product category

Medical Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC)

akta.pro secondary industry

Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)

Keywords

• Breath diagnostics
• Lung cancer screening
• Volatile organic compound analysis
• Nanosensor breath testing
• Noninvasive disease detection

Headquarters

HQ city

Hills

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. MyBreathPrint Device (Hardware) Sales: Sale of the MyBreathPrint handheld breath diagnostic device to clinicians and eventually home users. Device is initially available to clinicians only, with future home-use plans via connected mobile application.
2. Cloud-Based Data Analysis / SaaS: BreathPrint data captured by the device is sent to cloud-based platform for analysis and delivered to physician. Platform generates revenue through subscription or per-use analysis fees.
3. Professional Services & Clinical Partnerships: Engagement with clinical partners for validation studies and eventual commercialization through hospital and clinic partnerships.
4. Lung Cancer Detection & Monitoring Device: Partnership with S3 Connected Health to develop and market a lung cancer detection and monitoring device leveraging S3's Affinal digital health platform for custom mobile application and cloud solution.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Vocxi Health develops and commercializes MyBreathPrint, a handheld breath-based diagnostic device that uses a proprietary graphene-enhanced nanosensor array to detect volatile organic compounds (VOCs) in exhaled breath at parts-per-billion sensitivity. Captured electrochemical patterns are transmitted via a mobile connection to the cloud-based BreathML machine learning platform, which generates a unique "BreathPrint" and delivers disease-detection results (initially focused on lung cancer) to physicians within seconds of one minute of breathing.

Product overview

Vocxi Health offers MyBreathPrint as its primary product: a noninvasive, early disease detection system consisting of a handheld breath analyzer device (no bigger than a deck of cards) paired with the cloud-based BreathML machine learning platform. The system analyzes volatile organic compound (VOC) patterns from a one-minute breath sample to detect diseases including lung cancer. The MyBreathPrint device connects to a mobile application which transmits data to the cloud platform for immediate analysis, with results delivered to physicians within seconds. The technology was developed over a decade through collaboration with Boston Scientific and the University of Minnesota, and is protected by an extensive patent portfolio of 30+ issued patents with 30+ pending.

Differentiator

Problem solved

Functional benefit

Brands

• MyBreathPrint: The innovative, noninvasive early disease detection system that delivers accurate results with just one minute of breathing. Uses graphene-based nanosensors to detect volatile organic compounds (VOCs) in breath for disease detection, particularly focused on lung cancer initially.
• BreathML

Products and services

• MyBreathPrint Handheld breath-based diagnostic device that detects diseases such as lung cancer by analyzing volatile organic compound (VOC) patterns in exhaled breath using a graphene-enhanced nanosensor array with parts-per-billion sensitivity; connects to the BreathML cloud platform and delivers results to physicians within seconds. Initially deployed to clinicians and clinical study partners, with future plans for home use.
• BreathML Platform Cloud-based machine learning platform that receives electrochemical patterns from the MyBreathPrint device, generates unique BreathPrint profiles, and analyzes whether patients have disease or ailments to deliver results to physicians.
• MyBreathPrint Mobile Application Mobile application component that connects to the MyBreathPrint device to transmit breath analysis data to the BreathML cloud platform; planned to enable future home-based screening via phone or tablet connectivity.
• Handheld Miniaturized MyBreathPrint Device (with Forj Medical) Miniaturized, handheld version of the MyBreathPrint breath-based diagnostic device developed in partnership with Forj Medical, designed for improved manufacturability and clinical readiness for widespread screening and early detection of diseases such as lung cancer.

Quantifiable outcome

• 4x more accurate than other screening approaches for stage-one lung cancer detection
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Forj MedicalcoreStrategic or Co-development Partner · 9 March 2026Vocxi Health partnered with Forj Medical to develop a miniaturized version of its graphene-based breath diagnostics device for early disease detection. The collaboration resulted in a compact, handheld device with improved manufacturability and clinical readiness, aiming to enable widespread screening and early diagnosis.
• S3 Connected HealthcoreTechnology or Integration · 23 August 2023Vocxi Health and S3 Connected Health entered a partnership agreement to develop and market a lung cancer detection and monitoring device. Vocxi's BreathEZ device is combined with S3's Affinal digital health platform to create a custom mobile application and cloud-based solution. Companies plan to expand usage to other disease indications.
• University of MinnesotacoreStrategic or Co-development PartnerVocxi Health was born from a collaboration between a global medical device leader and the University of Minnesota. Greg Peterson led the collaboration team at the University of Minnesota Medical Devices Center for nearly ten years developing MyBreathPrint. The company originated from University of Minnesota technology and research.
• Boston ScientificcoreStrategic or Co-development PartnerVocxi Health's technology originated from collaboration between a global medical device leader (Boston Scientific) and the University of Minnesota. CTO Greg Sherwood was a Senior Fellow at Boston Scientific; COO Randy Schiestl was VP of R&D at Boston Scientific; CPO Raia Finc worked at Boston Scientific. Technology began with an innovation challenge at Boston Scientific.
• Mayo CliniccoreStrategic or Co-development PartnerCTO Greg Sherwood began developing MyBreathPrint after shadowing pulmonologists at Mayo Clinic who described challenges in lung cancer screening. Mayo Clinic collaboration contributed to the scientific foundation of the technology.
• MTEC (Medical Technology Enterprise Consortium)minorStrategic or Co-development PartnerStrategic partner listed on Vocxi Health's About page alongside Intricon and University of Minnesota.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Owlstone Medical: Owlstone Medical is the most directly comparable peer, developing breath-based diagnostics for multiple diseases including lung cancer using VOC analysis. Both companies pursue non-invasive breath biopsy approaches with platform technology spanning multiple indications.
• Biodesix: Biodesix is a lung cancer diagnostics company that has commercialized blood-based tests (e.g., Nodify Lung, VeriStrat) for lung nodule assessment and treatment guidance, targeting the same pulmonology and oncology clinical decision points as Vocxi's breath-based approach.
• Oncimmune: Oncimmune commercializes EarlyCDT Lung, a blood-based lung cancer detection test, and pursues multi-cancer screening applications. It is a direct competitor addressing the same clinical need (early lung cancer detection) through a different biomarker modality.
• NIOX Group (Circassia): NIOX commercializes exhaled breath-based diagnostic devices (measuring fractional exhaled nitric oxide) for asthma and respiratory inflammation. It is a direct peer in breath-based respiratory diagnostics with FDA-cleared, commercially deployed products.
• Spirosure (Fenom Pro): Spirosure develops the Fenom Pro breath-based VOC diagnostic for asthma, addressing respiratory disease through exhaled breath analysis. As a direct peer in VOC breath diagnostics for respiratory conditions, it competes for clinical research talent and pulmonology channel access.

Broad incumbents

• Veracyte: Veracyte is an established genomic diagnostics company with multiple commercialized tests including the Afirma thyroid test and the Percepta lung cancer test, directly competing with Vocxi in lung cancer diagnostics while operating across multiple cancer indications.
• Guardant Health: Guardant Health is a leading liquid biopsy company with commercialized oncology tests including lung cancer applications (Guardant360). As an established, well-capitalized incumbent in non-invasive cancer detection, it represents both a competitor and a potential strategic acquirer.

Emerging players

• Avisa Pharma: Avisa Pharma is developing a breath-based diagnostic for respiratory infections including tuberculosis detection. As an emerging player in breath diagnostics, it demonstrates the broader market opportunity but focuses on infectious disease rather than cancer.
• Menssana Research: Menssana Research provides breath-based diagnostic testing services focused on early detection of lung cancer and other diseases. It represents an alternative business model (lab services) versus Vocxi's device-and-platform approach in the same underlying breath diagnostics category.

Others

• Boston Scientific: Boston Scientific is a major medical device company from which Vocxi's technology originated and where multiple senior leaders (CTO, COO, CPO) previously held senior roles. It is a strategic enabler and potential acquirer rather than a direct competitor in breath diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vocxi-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vocxi Health